Barclays lowered the firm’s price target on Hinge Health (HNGE) to $60 from $65 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the security, design, and vertical-specific software group as part of its 2026 outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health: Tactical Expense Shift, Intact 2026 Growth and Cash Flow Support Buy Rating
- Hinge Health management to meet virtually with Citizens JMP
- Hinge Health 2.014M share Block Trade priced at $39.85
- Hinge Health 2.014M share Block Trade; price range $39.75-$40.84
- Hinge Health announces $250M share repurchase program